Angarus Therapeutics Overview
- Year Founded
-
2018
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
Angarus Therapeutics General Information
Description
Developer of immuno-oncology therapies designed to respond to the urgent needs of cancer treatment. The company's therapies develop checkpoint blockers on the innate immunity pathway that enhance the killing power of tumor-infiltrating lymphocytes and produce durable responses in a small fraction, enabling doctors to help patients by targeting immunological aspects of the tumor microenvironment.
Contact Information
Website
www.angarustx.comCorporate Office
- 321 Dedalera Drive
- Portola Valley, CA 94028
- United States
Corporate Office
- 321 Dedalera Drive
- Portola Valley, CA 94028
- United States
Angarus Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Out of Business | Completed | Out of Business | ||||
| 3. Secondary Transaction - Private | Completed | Clinical Trials - Phase 1 | ||||
| 2. Early Stage VC (Series A) | 22-Jun-2021 | $11.3M | $12.3M | Completed | Clinical Trials - Phase 1 | |
| 1. Seed Round | $1M | $1M | Completed | Startup |
Angarus Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Seed |
Angarus Therapeutics Patents
Angarus Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4422639-A1 | Enpp1 inhibitors as inhibitors of metastasis | Pending | 29-Oct-2021 | ||
| EP-4422639-A4 | Enpp1 inhibitors as inhibitors of metastasis | Pending | 29-Oct-2021 | ||
| WO-2023077083-A1 | Enpp1 inhibitors as inhibitors of metastasis | Inactive | 29-Oct-2021 | ||
| EP-4395786-A1 | Enpp1 inhibitors and immune cells expressing chimeric antigen receptors | Pending | 03-Sep-2021 | ||
| EP-4395786-A4 | Enpp1 inhibitors and immune cells expressing chimeric antigen receptors | Pending | 03-Sep-2021 | A61K40/42 |
Angarus Therapeutics FAQs
-
When was Angarus Therapeutics founded?
Angarus Therapeutics was founded in 2018.
-
Where is Angarus Therapeutics headquartered?
Angarus Therapeutics is headquartered in Portola Valley, CA.
-
What industry is Angarus Therapeutics in?
Angarus Therapeutics’s primary industry is Drug Discovery.
-
Is Angarus Therapeutics a private or public company?
Angarus Therapeutics is a Private company.
-
What is Angarus Therapeutics’s current revenue?
The current revenue for Angarus Therapeutics is .
-
How much funding has Angarus Therapeutics raised over time?
Angarus Therapeutics has raised $12.3M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process